Market News / Story
Seaport Therapeutics, Inc. (SPTX) Reports Phase 1 PK Showing 6.8x Bioavailability for GlyphAgo
·
Seaport Therapeutics reported Phase 1 PK data for GlyphAgo showing a 6.8-fold increase in agomelatine bioavailability and 10-fold lower PK variability vs unmodified drug. Phase 2/3 in GAD is planned for H1 2027; Phase 2a in GAD with sleep disturbance is underway. Material Details #DetailAI Analyst View16.8x bioavailability vs agomelatineHigher exposure at lower doses could improve efficacy and safety, supporting differentiation.210-fold lower PK variabilityMore…